Clinical Data Strengthens Cogenics Management Team with Strategic Appointments.

NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ: CLDA), a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as clinical diagnostics to improve patient care, announced today that it has appointed Robert Bondaryk, Ph.D., most recently Executive Vice President, General Manager and Business Development, Proteome Systems, Inc. and Vice President, Life Science and Drug Discovery, Fischer Scientific, LLC, to the position of General Manager and Unit Head, Cogenics. The company has also appointed Abdul Ally as Cogenics' Vice President of Laboratory Operations; he previously served as Director, Operations & Development at Sigma Proligo and Sigma Genosys.

Cogenics offers integrated services for genotyping, sequencing, gene expression and DNA and RNA extraction and biorepository, in both bioresearch and FDA-regulated environments. In his new position, Dr. Bondaryk will be working as a key member of Clinical Data's senior management team on Cogenics strategy, client development, refinement and enhancement of the business unit service offerings as well as the near term focus of managing the unit toward profitability. He will report to Drew Fromkin, Clinical Data President and CEO. Mr. Ally will manage day-to-day laboratory operations as well as be responsible other associated functions to rapidly achieve the company's objectives and goals. He will report to Dr. Bondaryk.

Commenting on the appointments, Drew Fromkin, Clinical Data's President and CEO said, "As a pioneer and leader in the field of genomic services, Cogenics already has a strong record of providing comprehensive pharmacogenomics and molecular services to the scientific community. As the industry evolves, Cogenics must continue to enhance its broad and comprehensive offerings while running its operations in a manner consistent with a services business. Bob Bondaryk has a sound balance of experience in the areas of healthcare services, diagnostics as well as bioresearch and distribution management. In addition, his combination of strong science and business skills coupled with his knowledge of our markets and clients will greatly benefit Cogenics and the other genomics activities within Clinical Data in both the US and abroad.

In addition, the skill sets of Dr. Bondaryk and Mr. Ally will bolster an already seasoned team and drive the business in the areas of strategic growth and profitability. As Clinical Data continues to introduce innovative, tailored service solutions and pursues growth and greater market share, we know Bob and Abdul will play a major role in achieving these goals."

Dr. Bondaryk said, "Cogenics already has established an enviable position as a trusted provider of a complete range of pharmacogenomics and molecular biology services to pharmaceutical, biotechnology and agribusiness companies and to clinical and academic bioscience research organizations. I am looking forward to working with Drew and the entire Cogenics team to build on this unique legacy by continuing to respond aggressively to the evolving genomic services needs of our client-customers as Science moves rapidly forward. We remain firmly committed to delivering the highest quality analysis and procedural excellence available anywhere and steadfast in our commitment to the many vitally important responsibilities our client-customers have entrusted to us. By contributing significantly to the success of our clients, we will share significantly in that success at Cogenics and Clinical Data, Inc."

At Proteome Systems, Dr. Bondaryk served as Executive Vice President and General Manager of the US division of the Sydney, Australia-based biotechnology company that used advanced proteomics technologies for the discovery of biomarkers for diagnosis, prognosis, and treatment. In this position, Dr. Bondaryk led US marketing and business development while maintaining a dialogue with pharmaceutical, biotech, and diagnostic companies and academic institutions globally. In addition, Dr. Bondaryk managed Proteome System's entry into the US pharma market via the successful integration of Woburn, Massachusetts based Eukarion, Inc., a small-molecule drug development company, after it was acquired.

Dr. Bondaryk also served as Vice President, Life Science and Drug Discovery at Fisher Scientific, LLC; Vice President of Corporate Development at Pharm-Eco Laboratories; Co-Founder and President of Medtech Capital, Inc.; and Senior Consultant at Arthur D. Little, Inc. Dr. Bondaryk has received his Ph.D. in Biochemistry from Harvard University and also completed an accelerated business curriculum for Ph.D.'s at Harvard, and he has an A.B. from Bowdoin College in Biology. He serves currently on the Drug Discovery Committee of the Massachusetts Biotechnology Council, the Life Sciences Alliance of the Greater Boston Chamber of Commerce, and the Corporation of Boston Biomedical Research Institute.

Mr. Ally's previous responsibilities at Sigma Proligo and Sigma Genosys included management of Operations and the global development efforts of 14 worldwide manufacturing sites to improve product quality and on time delivery while lowering manufacturing costs; designing and implementing new manufacturing processes, automation of instrumentation; development of emerging product lines in Custom DNA, RNA and Peptide manufacturing; managing DNA and Peptide Manufacturing, Chemistry and Engineering technology development groups; establishment of comprehensive metrics to monitor Performance; and increased site communication and ensuring continuous process improvements. Mr. Ally made significant improvements to Sigma Genosys Nucleic Acid Manufacturing Operations to ensure the successful implementation of the overall strategy to achieve a #1 position in the Global Market for nucleic acid manufacturing.

Mr. Ally has previously served as Director of Engineering at Marligen Biosciences, Inc.; Director of R&D Engineering and Senior Staff Scientist of the Genome Analysis Group at Life Technologies, Inc.; and DNA Sequencing Production at Lark Sequencing Technologies, Inc. Mr. Ally has also served as a faculty member in Cellular and Developmental Biology at Harvard University working on the Multiplex Genome Walking Project. He has received his M.Sc. in Molecular Biology from Howard University.

About Clinical Data, Inc.

Clinical Data, Inc. is a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as genetic tests to improve patient care. The Company, founded in 1972, is organized under three worldwide divisions segmented by service offerings and varying client constituents: PGxHealth(TM); Cogenics(TM); and Vital Diagnostics(TM). Clinical Data's Therapeutic Diagnostics(TM) division, PGxHealth, builds upon existing assets and know-how acquired from Genaissance Pharmaceuticals in the areas of genomics-based, genetic tests and therapeutic efficacy and safety biomarker development for drug utilization. PGxHealth plans to develop and introduce novel Therapeutic Diagnostics in some instances in combination with new and existing therapeutics. Clinical Data's Pharmacogenomics and Molecular Services(TM) division, Cogenics, consolidates the operations of Genaissance Pharmaceuticals, Inc., Lark Technologies, Inc. and Icoria, Inc., each acquired during 2005, and Genome Express SA, acquired in 2006. Cogenics provides a comprehensive range of molecular and pharmacogenomics services to pharmaceutical, biotech, academia, agricultural, and government clients. These services are offered in both research and regulated environments and have applications across the lifecycle of pharmaceutical product development including pharmacovigilance requirements post-launch. Clinical Data's Vital Diagnostics division consolidates the operations of Clinical Data Sales & Service, Inc., Vital Scientific NV, Vital Diagnostics Pty. Ltd., and Electa Lab s.r.l. This division serves the clinical laboratory in the traditional in-vitro diagnostics market worldwide with a focus on the physician's office, hospital and small-to-medium sized laboratory segments. With customers in approximately 100 countries, Vital Diagnostics has achieved a leading market share for instruments and reagents sold into moderately complex physicians' office laboratories within the United States. Clinical Data currently employs a staff of over 430. The Company is headquartered in Newton, Massachusetts with operations in Texas, Connecticut, RTP - North Carolina, Rhode Island, and California as well as internationally in the UK, France, the Netherlands, Italy and Australia. Furthermore, Clinical Data has numerous distribution, licensing, development and other collaborations with key partners.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about our ability to successfully integrate the operations, business, technology and intellectual property obtained in our recent acquisitions; our ability to obtain regulatory approval for, and successfully introduce our new products; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; competition from pharmaceutical, biotechnology and diagnostics companies; the strength of our intellectual property rights; the effect on the Company's operations and results of significant acquisitions or divestitures made by major competitors; the Company's ability to achieve expected synergies and operating efficiencies in all of its acquisitions, and to successfully integrate its operations; and those risks discussed and identified by Clinical Data in its public filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2006, and fiscal 2005 and 2006 quarterly reports on Forms 10-QSB and 10-Q.

Internet Website: www.clda.com